Meldola

Running trials

• Recruiting

  Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

  NCT07590934· Phase 1/2· Source

• Recruiting

  MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.

  NCT07607769· Source

• Active, not recruiting

  A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

  NCT03530397· Phase 1· Source

• Active, not recruiting

  To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

  NCT03330847· Phase 2· Source

• Active, not recruiting

  Savolitinib vs. Sunitinib in MET-driven PRCC.

  NCT03091192· Phase 3· Source

• Active, not recruiting

  Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

  NCT03043872· Phase 3· Source

• Active, not recruiting

  A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

  NCT02970318· Phase 3· Source

• Active, not recruiting

  Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

  NCT02477696· Phase 3· Source

• Active, not recruiting

  Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

  NCT02453282· Phase 3· Source

• Active, not recruiting

  An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

  NCT02213926· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

  NCT06973161· Source

• Completed

  Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

  NCT04642469· Phase 3· Source

• Completed

  Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

  NCT04249362· Phase 2· Source

• Completed

  AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT02151981· Phase 3· Source